 | Up a level |
Grob, J. -J., Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., Haney, P., Kaempgen, E., Karaszewska, B., Mauch, C., Miller, W. H., Jr., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S. and Hauschild, A. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann. Oncol., 25 (7). S. 1428 - 1437. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Hassel, J., Forschner, A., Bluhm, L., Heinzerling, L., Zimmer, L., Utikal, J., Kaehler, K., Schlaak, M., Loquai, C., Gutzmer, R., Kieker, F., Berking, C., Bender, A., Schneider, L., Enk, A., Garbe, C., Weichenthal, M., Schadendorf, D., Hauschild, A. and Mohr, P. (2016). Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP). J. Dtsch. Dermatol. Ges., 14. S. 9 - 10. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Heppt, M. V., Schlaak, M., Eigentler, T. K., Kaehler, K. C., Kiecker, F., Loquai, C., Meier, F., Tomsitz, D., Brenner, N., Niesert, A. C., Thonke, R., Hauschild, A. and Berking, C. (2017). Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann. Oncol., 28 (12). S. 3104 - 3108. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041